I’ve spent 11 years in pharma commercial ops and managed markets. If I had a dollar for every time a team member told me they were going to a conference for "networking," I’d be retired in Tuscany. Networking is a byproduct, not a strategy. If you aren't coming back with specific intel on payer friction or health system formulary blockages, you’re just drinking overpriced hotel coffee.
Rare disease and specialty pharmacy operations are high-stakes environments. You aren't just selling a pill; you’re selling a complex hub services ecosystem and an evidence generation dossier. Here is my breakdown of where to actually go, based on my running spreadsheet of "who you actually meet" versus the marketing brochure promises.
The Payer vs. Prescriber Trap
Most commercial teams make the mistake of treating a prescriber conference like a market access summit. They are not the same. Prescribers care about patient clinical outcomes and the ease of the Prior Authorization (PA) process. Payers care about HTA pressure, budget impact models, and the sustainability of specialty pharmacy models.
If you are in a rare disease summit, you need to understand the difference between the clinical value proposition and the financial value proposition. Don't waste your time pitching a clinical lead on your net pricing strategy, and don't waste a payer medical director's time with a demo of your patient support app.
Where to Spend Your Budget
I track every event I attend. I keep a spreadsheet that logs "Role of the lead contact" and "Tangible outcome." Here are the three events that have actually delivered actionable data for my teams.
1. AMCP (Academy of Managed Care Pharmacy)
AMCP is the gold standard for anyone working in managed care strategy. This is not a "sales" conference; it’s a policy and operations gauntlet. You will meet the people who actually design the formulary tiers and utilization management criteria.
- Why attend: You need to talk about PA hurdles and the shifting landscape of value-based contracting. The "Monday" question: Can we change our clinical evidence summary to address the specific objections raised in the AMCP educational tracks?
2. The Health Management Academy (THMA)
THMA is where the health system executives live. If your specialty product requires hospital formulary adoption or complex infusion center billing, this is your event. You aren't meeting pharmacy managers here; you are meeting C-suite executives who view your drug through the lens of institutional budget impacts.
3. Association of Cancer Care Centers (ACCC)
For oncology-focused rare disease, ACCC is essential. It provides a look at how provider organizations are actually executing on specialty pharmacy models. It’s less about the drug and more about the "business of delivery"—how the practice handles the financial risk of high-cost therapies.
The "Who Actually Attends" Spreadsheet: A Sample
I don't trust brochures. I trust data. Here is a snapshot of how I categorize attendance based on my personal event tracking:
Digital Tools and the "Infrastructure" Conversation
Rare disease access isn't just human-to-human. It’s increasingly about the digital interface. I’m constantly looking at how providers interact with our evidence generation portals and reimbursement dashboards.
When you are scouting a conference or a digital vendor, pay attention to the "clutter." I often look at how a company manages their own web presence as a proxy for how they manage data. For instance, notice the simple UI elements like a Cookie Law Info plugin or a clearly gated resource center. If their digital onboarding is a disaster, their reimbursement portal is going to be a disaster. If they can’t handle a simple consent banner effectively, they definitely aren't going to handle sensitive HIPAA-compliant patient data in a hub services model.
Pricing, Affordability, and HTA Pressure
The conversation at these events has shifted dramatically Look at this website toward HTA (Health Technology Assessment) pressure. It used to be enough to show a clinical benefit. Now, you have to defend the price in the context of the total cost of care.
If you are at a hub services conference, stop talking about "streamlined" patient enrollment. That’s a buzzword. Start talking about the integration of digital tools in evidence generation that prove, in real-time, that your drug is keeping patients out of the ER. That is your actual value proposition for the specialty pharmacy provider.
The "Monday Morning" Reality Check
After any conference, I force my team to answer the "What would I do differently on Monday?" question. If they can’t point to a specific process or contract that needs a tweak, the conference was a failure.
Audit your PA forms: Did you hear a common complaint about your required clinical data? Update the form. Review the Hub Portal: Is the user experience intuitive, or does it look like a 2005-era website? If it’s the latter, the dropout rate is your fault. Payer Outreach: Did you meet someone who actually oversees the P&T committee? Email them a link to the specific study they asked about. Do not send a general "nice to meet you" note.Final Thoughts: Stop Chasing Buzzwords
"Synergy" and "streamline" are words used by people who don't have a plan. In market access, precision is everything. Whether you are at a high-level THMA session or a niche rare disease summit, focus on the friction points.
Who is blocking the formulary? Why is the hub enrollment stalling? How does the payer view our pricing strategy relative to the clinical evidence we've published? Those are the only questions that matter. If you aren't tracking your ROI through these specific, hard-won insights, you’re not doing operations; you’re just doing tourism.